Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | PDE5A | O76074 | 14/20 | 0.52 |
| ▸ | GUCY1A1 | Q02108 | 4/20 | 0.46 |
| ▸ | GUCY1B1 | Q02153 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15111627 | 0.91 | PDE5A (0.55) | ADORA3KCNH2PDE5A | |
| SCHEMBL326641 | 0.87 | ADORA3 (0.58) | ADORA3KCNH2PDE5A | |
| SCHEMBL15120862 | 0.84 | ADORA3 (0.52) | ADORA3KCNH2PDE5A | |
| SCHEMBL15111716 | 0.83 | PDE5A (0.56) | ADORA3KCNH2PDE5A | |
| SCHEMBL15111795 | 0.82 | PDE5A (0.54) | ADORA3KCNH2PDE5A | |
| SCHEMBL15111726 | 0.81 | PDE5A (0.59) | ADORA3KCNH2PDE5A | |
| SCHEMBL9913960 | 0.81 | ADORA3 (0.51) | ADORA3KCNH2PDE5A | |
| SCHEMBL16276125 | 0.81 | PDE5A (0.55) | ADORA3KCNH2PDE5A | |
| SCHEMBL15111665 | 0.80 | PDE5A (0.55) | ADORA3KCNH2PDE5A | |
| SCHEMBL9913980 | 0.79 | ADORA3 (0.48) | ADORA3KCNH2PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505786-B2 | Substituted annulated triazines and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-29 | — | — | US | disclosed |
| US-20150274754-A1 | SUBSTITUTED ANNULATED TRIAZINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-01 | — | — | US | disclosed |
| US-20140357637-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274754-A1 | SUBSTITUTED ANNULATED TRIAZINES AND USE THEREOF | TPMT, GOT2, TYMP | ADORA3 1176/4885KCNH2 1311/4885PDE5A 1225/4885 |
| US-20140357637-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | TYMP, DPYD, TYMS | ADORA3 724/4885KCNH2 2585/4885PDE5A 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.